Platinum-based API line running
Heraeus Pharmaceutical Ingredients (HPI) has announced that its new production line for platinum-based pharmaceutical ingredients at its headquarters in Hanau, Germany, is now running at full speed and customers have already received the first deliveries of APIs. The company launched the project in late 2018 in response to growing demand for oncology drugs and imminent shortages. HPI, a business line of Heraeus Precious Metals, is world’s largest supplier of platinum-based HPAPIs, which are used in numerous therapies, notably lung, colorectal, ovarian and testicular cancer.
RELATED ARTICLES
Peptides CDMO AmbioPharm, has broken ground on a 650 m2, $28 million expansion project at its Shanghai manufacturing site. This is due to be complete in 2H 2025 and will produce over 8 tonnes/year of crude peptide.
Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.
Biosynth, which supplies critical raw materials and services for diagnostics, vaccines and pharmaceuticals, has officially opened its Biosynth Biological Technology site at Lifebay, a technology park in Suzhou, China.
At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitional year in 2023.
At CPHI in Milan in October, eight Indian CDMOs announced that they have formed a trade group to raise the profile of India’s drug services sector and make it a destination of choice.
CatSci has opened a second oligonucleotides laboratory, which it will use “to introduce novel workflows for the rapid production of vast numbers of oligos at a scale optimised for rapid screening”.
